Profile data is unavailable for this security.
About the company
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
- Revenue in USD (TTM)590.09m
- Net income in USD-15.86m
- Incorporated1989
- Employees965.00
- LocationAmarin Corporation PLCGemini House, Bartholomews WalkDUBLIN FK7 9JQIrelandIRL
- Phone+353 16699020
- Websitehttp://www.amarincorp.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc. | 143.43m | -16.11m | 2.29bn | 115.00 | -- | 3.29 | 982.23 | 15.99 | -0.9813 | -0.9813 | 8.62 | 43.37 | 0.1026 | 2.06 | 5.23 | 1,247,235.00 | -1.15 | 26.66 | -1.19 | 33.41 | 85.63 | 95.04 | -11.23 | 150.38 | 19.96 | 0.226 | 0.3947 | -- | -52.17 | 13.26 | 337.26 | 120.68 | 20.47 | -- |
| Zymeworks Inc | 25.15m | -214.89m | 2.39bn | 325.00 | -- | 5.53 | -- | 95.06 | -4.49 | -4.49 | 0.5184 | 9.44 | 0.0518 | -- | 7.17 | 98,234.38 | -44.23 | -34.90 | -52.15 | -41.57 | -- | -- | -854.51 | -158.31 | -- | -- | 0.0003 | -- | -44.28 | 77.64 | -297.84 | -- | 118.13 | -- |
| Tilray Inc | 200.86m | -488.26m | 2.41bn | 1.65k | -- | 9.92 | -- | 11.98 | -4.37 | -4.37 | 1.70 | 1.82 | 0.2084 | 2.48 | 6.60 | 122,027.90 | -50.66 | -- | -58.69 | -- | -23.81 | -- | -243.09 | -- | 1.61 | -4.88 | 0.7221 | -- | 287.15 | -- | -374.24 | -- | -- | -- |
| Stoke Therapeutics Inc | 0.00 | -47.84m | 2.41bn | 44.00 | -- | 11.66 | -- | -- | -1.47 | -1.47 | 0.00 | 5.77 | 0.00 | -- | -- | -- | -21.81 | -- | -22.40 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -158.17 | -- | -- | -- |
| Arcus Biosciences Inc | 77.78m | -87.60m | 2.49bn | 139.00 | -- | 4.58 | -- | 32.06 | -1.90 | -1.90 | 1.54 | 8.39 | 0.1513 | -- | 18.91 | 559,568.40 | -17.04 | -- | -20.76 | -- | -- | -- | -112.63 | -- | -- | -- | 0.00 | -- | 79.58 | -- | -70.81 | -- | -- | -- |
| Sorrento Therapeutics Inc | 41.52m | -289.78m | 2.53bn | 310.00 | -- | 11.93 | -- | 61.06 | -1.45 | -1.45 | 0.206 | 0.8083 | 0.0714 | 2.71 | 3.15 | 133,919.40 | -52.43 | -29.30 | -57.66 | -33.95 | 78.85 | 88.03 | -734.39 | -290.10 | 1.13 | -10.18 | 0.5362 | -- | 48.31 | 52.39 | -43.49 | -- | 117.07 | -- |
| Amarin Corporation plc (ADR) | 590.09m | -15.86m | 2.55bn | 965.00 | -- | 4.23 | -- | 4.32 | -0.0436 | -0.0436 | 1.56 | 1.56 | 0.6459 | 1.25 | 4.70 | 611,488.10 | -1.74 | -28.36 | -2.49 | -45.57 | 78.42 | 75.50 | -2.69 | -38.13 | 2.27 | -- | 0.0154 | -- | 87.49 | 51.30 | 80.55 | -- | -- | -- |
| ADC Therapeutics SA | -100.00bn | -100.00bn | 2.56bn | 179.00 | -- | 6.81 | -- | -- | -- | -- | -- | 4.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | 105.26 | -- | 5.37 | -- | -- | -- |
| Medifast Inc | 840.56m | 94.75m | 2.60bn | 550.00 | 27.65 | 18.56 | 25.67 | 3.09 | 7.99 | 7.99 | 70.86 | 11.90 | 3.66 | 4.57 | 801.30 | 1,528,295.00 | 41.25 | 28.14 | 70.22 | 39.12 | 74.55 | 75.19 | 11.27 | 9.66 | 1.57 | -- | 0.00 | 49.96 | 42.45 | 20.13 | 39.66 | 29.95 | 7.44 | -- |
| Simply Good Foods Co | 895.64m | 61.99m | 2.62bn | 300.00 | 43.95 | 2.09 | 32.79 | 2.93 | 0.6234 | 0.6234 | 9.00 | 13.13 | 0.4444 | 6.48 | 10.70 | 2,985,467.00 | 3.08 | 3.48 | 3.21 | 3.65 | 39.77 | 41.68 | 6.92 | 6.19 | 2.69 | 4.04 | 0.3133 | 0.00 | 56.03 | -- | -27.00 | -- | -- | -- |
| Deciphera Pharmaceuticals Inc | 22.60m | -270.97m | 2.66bn | 255.00 | -- | 4.65 | -- | 117.79 | -5.00 | -5.00 | 0.4162 | 10.05 | 0.0345 | -- | -- | 88,631.38 | -41.39 | -- | -44.94 | -- | 99.29 | -- | -1,198.91 | -- | 9.26 | -- | 0.00 | -- | -- | -- | -92.54 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 10.42m | -206.89m | 2.67bn | 330.00 | -- | 3.76 | -- | 256.34 | -3.22 | -3.22 | 0.1626 | 8.85 | 0.0198 | -- | -- | 31,573.70 | -39.34 | -32.91 | -42.20 | -34.57 | 92.18 | -- | -1,985.63 | -85,509.11 | 19.51 | -- | 0.00 | -- | -- | -36.29 | 4.77 | -- | 126.46 | -- |
| Karuna Therapeutics Inc | 0.00 | -52.32m | 2.76bn | 19.00 | -- | 7.73 | -- | -- | -1.99 | -1.99 | 0.00 | 13.34 | 0.00 | -- | -- | 0.00 | -19.79 | -- | -20.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -151.01 | -- | -- | -- |
| Allovir Inc | -100.00bn | -100.00bn | 2.78bn | 32.00 | -- | 7.04 | -- | -- | -- | -- | -- | 6.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -85.46 | -- | -192.29 | -- | -- | -- |
| Xencor Inc | 84.36m | -82.55m | 2.79bn | 166.00 | -- | 4.89 | -- | 33.03 | -1.45 | -1.45 | 1.48 | 9.91 | 0.1266 | -- | 5.84 | 508,168.70 | -12.39 | -1.77 | -13.78 | -2.10 | -- | -- | -97.86 | -9.18 | -- | -- | 0.00 | -- | 285.93 | 75.10 | 138.17 | -- | 37.03 | -- |
| Axsome Therapeutics Inc | 0.00 | -98.54m | 2.79bn | 45.00 | -- | 20.61 | -- | -- | -2.70 | -2.70 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -79.45 | -67.10 | -94.20 | -82.05 | -- | -- | -- | -- | -- | -65.16 | 0.262 | -- | -- | -- | -120.71 | -- | -- | -- |
Data as of Jan 22 2021. Currency figures normalised to Amarin Corporation PLC's reporting currency: US Dollar USD
21.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Sep 2020 | 32.02m | 8.18% |
| Eversept Partners LPas of 30 Sep 2020 | 10.65m | 2.72% |
| Tavistock Life Sciences Co. (Investment Management)as of 30 Sep 2020 | 7.00m | 1.79% |
| D. E. Shaw & Co. LPas of 30 Sep 2020 | 6.86m | 1.75% |
| Avoro Capital Advisor LLCas of 30 Sep 2020 | 6.00m | 1.53% |
| Grosvenor Capital Management LPas of 30 Sep 2020 | 5.42m | 1.39% |
| Artisan Partners LPas of 30 Sep 2020 | 5.19m | 1.33% |
| Avidity Partners Management LPas of 30 Sep 2020 | 4.51m | 1.15% |
| Rock Springs Capital Management LPas of 30 Sep 2020 | 4.35m | 1.11% |
| BlackRock Fund Advisorsas of 30 Sep 2020 | 3.63m | 0.93% |
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
